Transglutaminase for Protein Drug Modification: Pegylation and beyond

Biocatalysis for Green Chemistry and Chemical Process Development

Volumn , Issue , 2011, Pages 151-172

  Hu, Sean ^a   Yin, Yifeng ^b  

^a Novozymes Biotech Inc   (United States)

^b Trinity Biosystems   (United States)

Author keywords

As the most successful method extending half life and minimizing immunogenicity; Challenging and impossible; Of given protein at specific site; PEGylation emerging; Tailor made mTGase for protein drug site specific modification chemicals; Transglutaminase for protein drug modification pegylation and beyond

Indexed keywords

EID: 84886071894     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118028308.ch6     Document Type: Chapter

References (81)

1. Abuchowski A, McCoy JR, Palczuk NC, van Es T, Davis FF. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem 1977;252:3582-3586.
2. Abuchowski A, van Es T, Palczuk NC, Davis FF. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem 1977;252:3578-3581.
3. Bailon P, Won CY. PEG-modified biopharmaceuticals. Expert Opin Drug Deliv 2009;6:1-16.
4. Veronese FM, Mero A. The impact of PEGylation on biological therapies. BioDrugs 2008;22:315-329.
5. Sergi M, Caboi F, Maullu C, Orsini G, Tonon G. Enzymatic techniques for PEGylation of biopharmaceuticals. In: Veronese FM, editor. PEGylated protein drugs: basic science and clinical applications. Springer, Basel, 2009; pp 75-88.
6. Kinstler OB, Brems DN, Lauren SL, Paige AG, Hamburger JB, Treuheit MJ. Characterization and stability of N-terminally PEGylated rhG-CSF. Pharm Res 1996;13:996-1002.
7. Rosendahl MS, Doherty DH, Smith DJ, Carlson SJ, Chlipala EA, Cox GN. A long-acting, highly potent interferon alpha-2 conjugate created using site-specific PEGylation. Bioconjug Chem 2005;16:200-207.
8. Cox G. Derivatives of growth hormone and related proteins. WO 99/03887. 1999.
9. Lee S, McNemar C. Substantially pure histidine-linked protein polymer conjugates. US 5,985,263. 1999.
10. Zalipsky S, Meno-Rudolph S. Hydrazide derivatives of polyethylene glycol and their bioconjugates. In: Harris JM, Zalipsky S, editors. Polyethylene glycol chemistry and biological applications (ACS Symposium Series). 1st ed. Washington (DC): American Chemical Society; 1997. pp. 318-341.
11. Levy Y, Hershfield MS, Fernandez-Mejia C, Polmar SH, Scudiery D, Berger M, Sorensen RU. Adenosine deaminase deficiency with late onset of recurrent infections: response to treatment with polyethylene glycol-modified adenosine deaminase. J Pediatr 1988;113:312-317.
12. Graham ML. Pegaspargase: a review of clinical studies. Adv Drug Deliv Rev 2003;55:1293-1302.
13. Youngster S, Wang YS, Grace M, Bausch J, Bordens R, Wyss DF. Structure, biology, and therapeutic implications of pegylated interferon alpha-2b. Curr Pharm Des 2002;8:2139-2157.
14. Foser S, Schacher A, Weyer KA, Brugger D, Dietel E, Marti S, Schreitmuller T. Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon alpha-2a (PEGASYS). Protein Expr Purif 2003;30:78-87.
15. Pradhananga S, Wilkinson I, Ross RJ. Pegvisomant: structure and function. J Mol Endocrinol 2002;29:11-14.
16. Curran MP, McCormack PL. Methoxy polyethylene glycol-epoetin beta: a review of its use in the management of anaemia associated with chronic kidney disease. Drugs 2008;68:1139-1156.
17. Rivkin A. Certolizumab pegol for the management of Crohn's disease in adults. Clin Ther 2009;31:1158-1176.
18. Harris G. The future of biotech: the 2010 guide to emerging markets and technology. Atlanta, GA: AHC Media LLC; 2009.
19. Jorgensen KE, Moller JV. Use of flexible polymers as probes of glomerular pore size. Am J Physiol 1979;236:F103-F111.
20. Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S, Hepatitis C Intervention Therapy Group. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther 2000;68:556-567.
21. Macdougall IC, Eckardt KU. Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia. Lancet 2006;368:947-953.
22. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 2001;16 Suppl 3:3-13.
23. Ramakrishnan B, Boeggeman E, Qasba PK. Novel method for in vitro O-glycosylation of proteins: application for bioconjugation. Bioconjug Chem 2007;18:1912-1918.
24. Ramakrishnan B, Boeggeman E, Qasba PK. Applications of glycosyltransferases in the site-specific conjugation of biomolecules and the development of a targeted drug delivery system and contrast agents for MRI. Expert Opin Drug Deliv 2008;5:149-153.
25. Pasek M, Ramakrishnan B, Boeggeman E, Manzoni M,Waybright TJ, Qasba PK. Bioconjugation and detection of lactosamine moiety using alpha1,3-galactosyltransferase mutants that transfer C2-modified galactose with a chemical handle. Bioconjug Chem 2009;20:608-618.
26. Qasba PK, Boeggeman E, Ramakrishnan B. Site-specific linking of biomolecules via glycan residues using glycosyltransferases. Biotechnol Prog 2008;24:520-526.
27. Boeggeman E, Ramakrishnan B, Pasek M, Manzoni M, Puri A, Loomis KH, Waybright TJ, Qasba PK. Site specific conjugation of fluoroprobes to the remodeled Fc N-glycans of monoclonal antibodies using mutant glycosyltransferases: application for cell surface antigen detection. Bioconjug Chem 2009;20:1228-1236.
28. Chen T, Embree HD, Wu LQ, Payne GF. In vitro protein-polysaccharide conjugation: tyrosinase-catalyzed conjugation of gelatin and chitosan. Biopolymers 2002;64:292-302.
29. Demolliens A, Boucher C, Durocher Y, Jolicoeur M, Buschmann MD, De Crescenzo G. Tyrosinase-catalyzed synthesis of a universal coil-chitosan bioconjugate for protein immobilization. Bioconjug Chem 2008;19:1849-1854.
30. Quaedflieg PJLM, Cusan C, Ritzen B, Dias A. Enzymatic conjugation of bioactive moieties. WO2009/101178. 2009.
31. Chang TK, Jackson DY, Burnier JP, Wells JA. Subtiligase: a tool for semisynthesis of proteins. Proc Natl Acad Sci USA 1994;91:12544-12548.
32. Mahrus S, Trinidad JC, Barkan DT, Sali A, Burlingame AL, Wells JA. Global sequencing of proteolytic cleavage sites in apoptosis by specific labeling of protein N termini. Cell 2008;134:866-876.
33. Furter R. Expansion of the genetic code: site-directed p-fluoro-phenylalanine incorporation in Escherichia coli. Protein Sci 1998;7:419-426.
34. Cho HS, Daniel TO, Dimarchi RD, Hays A-M, Wilson TE, Sim B-C, Litzinger DC. Modified human growth hormone. US20060189529. 2006.
35. Connor RE, Piatkov K, Varshavsky A, Tirrell DA. Enzymatic N-terminal addition of noncanonical amino acids to peptides and proteins. Chembiochem 2008;9:366-369.
36. Griffin M, Casadio R, Bergamini CM. Transglutaminases: nature's biological glues. Biochem J 2002;368:377-396.
37. Folk JE, Chung SI. Molecular and catalytic properties of transglutaminases. Adv Enzymol Relat Areas Mol Biol 1973;38:109-191.
38. Folk JE. Transglutaminases. Annu Rev Biochem 1980;49:517-531.
39. Muszbek L, Yee VC, Hevessy Z. Blood coagulation factor XIII: structure and function. Thromb Res 1999;94:271-305.
40. Groenen PJ, Smulders RH, Peters RF, Grootjans JJ, van den Ijssel PR, Bloemendal H, de Jong WW. The amine-donor substrate specificity of tissue-type transglutaminase. Influence of amino acid residues flanking the amine-donor lysine residue. Eur J Biochem FEBS 1994;220:795-799.
41. Hettasch JM, Peoples KA, Greenberg CS. Analysis of factor XIII substrate specificity using recombinant human factor XIII and tissue transglutaminase chimeras. J Biol Chem 1997;272:25149-25156.
42. Folk JE, Cole PW. Structural requirements of specific substrates for guinea pig liver transglutaminase. J Biol Chem 1965;240:2951-2960.
43. Gorman JJ, Folk JE. Structural features of glutamine substrates for transglutaminases. Specificities of human plasma factor XIIIa and the guinea pig liver enzyme toward synthetic peptides. J Biol Chem 1981;256:2712-2715.
44. Gorman JJ, Folk JE. Structural features of glutamine substrates for transglutaminases. Role of extended interactions in the specificity of human plasma factor XIIIa and of the guinea pig liver enzyme. J Biol Chem 1984;259:9007-9010.
45. Board PG, Pierce K, Coggan M. Expression of functional coagulation factor XIII in Escherichia coli. Thromb Haemost 1990;63:235-240.
46. Gillet SM, Chica RA, Keillor JW, Pelletier JN. Expression and rapid purification of highly active hexahistidine-tagged guinea pig liver transglutaminase. Protein Expr Purif 2004;33:256-264.
47. Ikura K, Tsuchiya Y, Sasaki R, Chiba H. Expression of guinea-pig liver transglutaminase cDNA in Escherichia coli. Amino-terminal N alpha-acetyl group is not essential for catalytic function of transglutaminase. Eur J Biochem FEBS 1990;187:705-711.
48. Bishop PD, Teller DC, Smith RA, Lasser GW, Gilbert T, Seale RL. Expression, purification, and characterization of human factor XIII in Saccharomyces cerevisiae. Biochemistry 1990;29:1861-1869.
49. Coggan M, Baker R, Miloszewski K, Woodfield G, Board P. Mutations causing coagulation factor XIII subunit A deficiency: characterization of the mutant proteins after expression in yeast. Blood 1995;85:2455-2460.
50. Gao J, Hooker BS, Anderson DB. Expression of functional human coagulation factor XIII A-domain in plant cell suspensions and whole plants. Protein Expr Purif 2004;37:89-96.
51. Rao RU, Chandrashekar R, Mehta K. Transglutaminases of lower organisms. Prog Exp Tumor Res 2005;38:209-222.
52. Ando H, Adachi M, Umeda K, Matsuura A, Nonaka M, Uchio R, Tanaka H, Motoki M. Purification and characterization of a novel transglutaminase derived from microorganisms. Agric Biol Chem 1989;53:2613-2617.
53. Motoki M, Seguro K. Transglutaminase and its use for food processing. Trends Food Sci Technol 1998;9:204-210.
54. Zhu Y, Rinzema A, Tramper J, Bol J. Microbial transglutaminase-a review of its production and application in food processing. Appl Microbiol Biotechnol 1995;44:277-282.
55. Yokoyama K, Nio N, Kikuchi Y. Properties and applications of microbial transglutaminase. Appl Microbiol Biotechnol 2004;64:447-454.
56. Ohtsuka T, Ota M, Nio N, Motoki M. Comparison of substrate specificities of transglutaminases using synthetic peptides as acyl donors. Biosci Biotechnol Biochem 2000;64:2608-2613.
57. Ohtsuka T, Sawa A, Kawabata R, Nio N, Motoki M. Substrate specificities of microbial transglutaminase for primary amines. J Agric Food Chem 2000;48:6230-6233.
58. Tagami U, Shimba N, Nakamura M, Yokoyama K, Suzuki E, Hirokawa T. Substrate specificity of microbial transglutaminase as revealed by three-dimensional docking simulation and mutagenesis. Protein Eng Des Sel 2009;22:747-752.
59. Taguchi S, Nishihama KI, Igi K, Ito K, Taira H, Motoki M, Momose H. Substrate specificity analysis of microbial transglutaminase using proteinaceous protease inhibitors as natural model substrates. J Biochem 2000;128:415-425.
60. Zhu Y, Tramper J. Novel applications for microbial transglutaminase beyond food processing. Trends Biotechnol 2008;26:559-565.
61. Meusel M. Synthesis of hapten-protein conjugates using microbial transglutaminase. Methods Mol Biol 2004;283:109-123.
62. Lin CW, Ting AY. Transglutaminase-catalyzed site-specific conjugation of smallmolecule probes to proteins in vitro and on the surface of living cells. J Am Chem Soc 2006;128:4542-4543.
63. Sato H, Ikeda M, Suzuki K, Hirayama K. Site-specific modification of interleukin-2 by the combined use of genetic engineering techniques and transglutaminase. Biochemistry 1996;35:13072-13080.
64. Sato H. Enzymatic procedure for site-specific pegylation of proteins. Adv Drug Deliv Rev 2002;54:487-504.
65. Sato H, Hayashi E, Yamada N, Yatagai M, Takahara Y. Further studies on the site-specific protein modification by microbial transglutaminase. Bioconjug Chem 2001;12:701-710.
66. Pool C. Formation of novel erythropoietin conjugates using transglutaminase. US6995245. 2004.
67. Tonon G, Orsini G, Schrepfer R, Taylor G, Sergi M. G-CSF Site-Specific Mono- Conjugates. WO2008/017603. 2008.
68. Maullu C, Raimondo D, Caboi F, Giorgetti A, Sergi M, Valentini M, Tonon G, Tramontano A. Site-directed enzymatic PEGylation of the human granulocyte colonystimulating factor. FEBS J 2009;276:6471-6450.
69. Finn RF. PEGylation of human growth hormone: strategies and properties. In: Veronese FM, editor. PEGylated protein drugs: basic science and clinical applications. Springer, Basel, 2009; pp. 187-203.
70. Wu Z, Huang J, Liu C. Biological modifying and recombinant human growth hormone compound and preparing method thereof. CN1528787.
71. D'orwald F, Johansen N, Iversen L. Transglutaminase mediated conjugation of growth hormone. WO/2006/134148. 2006.
72. Leblanc A, Gravel C, Labelle J, Keillor JW. Kinetic studies of guinea pig liver transglutaminase reveal a general-base-catalyzed deacylation mechanism. Biochemistry 2001;40:8335-8342.
73. Kashiwagi T, Yokoyama K, Ishikawa K, Ono K, Ejima D, Matsui H, Suzuki E. Crystal structure of microbial transglutaminase from Streptoverticillium mobaraense. J Biol Chem 2002;277:44252-44260.
74. Hu S, Zhao X, Jianhua W, Chang C, Nørskov-Lauritsen L, Su J. Transglutaminase variants with improved specificity. WO/2008/102007. 2008.
75. Shimba N, Shinohara M, Yokoyama K, Kashiwagi T, Ishikawa K, Ejima D, Suzuki E. Enhancement of transglutaminase activity by NMR identification of its flexible residues affecting the active site. FEBS Lett 2002;517:175-179.
76. Zhao X, Shaw AC, Wang J, Chang CC, Deng J, Su J. A novel high-throughput screening method for microbial transglutaminases with high specificity toward Gln141 of human growth hormone. J Biomol Screen 2010;15:206-212.
77. Touraine P, D'Souza GA, Kourides I, Abs R, Barclay P, Xie R, Pico A, Torres-Vela E, Ekman B. Lipoatrophy in GH deficient patients treated with a long-acting pegylated GH. Eur J Endocrinol 2009;161:533-540.
78. Finn RF, Liao W, Siegel NR. Chemically-modified human growth hormone conjugates. US2004/0038892A1. 2004.
79. Besheer A, Hertel TC, Kressler J, Mader K, Pietzsch M. Enzymatically catalyzed HES conjugation using microbial transglutaminase: proof of feasibility. J Pharm Sci 2009;98:4420-4428.
80. Valdivia A, Villalonga R, Di Pierro P, Perez Y, Mariniello L, Gomez L, Porta R. Transglutaminase-catalyzed site-specific glycosidation of catalase with aminated dextran. J Biotechnol 2006;122:326-333.
81. Greco F, Vicent MJ. Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv Drug Deliv Rev 2009;61:1203-1213.